Targeting the full neoantigen landscape: DNA vaccine design and personalization in cancer immunotherapy

“...the greater the number of neoantigens targeted, the stronger the immune response, the better the clinical response, and the more favorable the overall survival.”

Ashling Cannon, Commissioning Editor, Vaccine Insights, speaks with Jian Yan, Vice President, Research and Discovery, Geneos Therapeutics, USA, about personalized therapeutic cancer vaccine development. They discuss neoantigen prioritization strategies, the architectural features of DNA vaccines that drive cytotoxic T cell responses, methods for tracking T cell tumor infiltration, and the modality-specific strengths and limitations that inform the case for combination approaches in the field.

Please enter your email to access content Read now